Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Aralez Bio

Explore full profile

High-quality, sustainable noncanonical amino acids for innovative drug discovery and manufacturing

Berkeley, United StatesFounded 2019Biotech & Life Sciences
Valuation $50–100M Last recorded · 2024
Headcount <100 Current team size
Total funding $10–50M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Aralez Bio and the history behind them.

About Aralez Bio

Aralez Bio is a cutting-edge startup specializing in the production of high-quality, sustainable noncanonical amino acids, which are essential components in the development of peptide drugs. These amino acids are often difficult to manufacture, leading to high costs, long lead times, and supply chain issues. However, Aralez Bio leverages unique enzymatic technology to produce these amino acids more efficiently, affordably, and in an environmentally friendly manner.

The company primarily serves clients in the pharmaceutical and biotechnology sectors, including Fortune 500 companies and peptide manufacturers. These clients rely on Aralez Bio's products to develop next-generation therapeutics, such as peptide drugs, small molecules, and drug conjugates. By providing a more cost-effective and sustainable solution, Aralez Bio helps its clients reduce production timelines and costs, making drug discovery and manufacturing more accessible and efficient.

Aralez Bio operates in the biotechnology and pharmaceutical markets, focusing on the niche segment of noncanonical amino acids. Its business model revolves around the production and sale of these amino acids to pharmaceutical companies and research institutions. The company generates revenue by selling its amino acids in various quantities, from small-scale research needs to large-scale manufacturing demands.

In summary, Aralez Bio is revolutionizing the production of noncanonical amino acids, offering a cheaper, greener, and more efficient solution for the pharmaceutical and biotechnology industries. By addressing the challenges of high costs and supply chain uncertainties, Aralez Bio is poised to play a significant role in the future of drug discovery and development.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2019
Headquarters
Berkeley, United States
Employees
38
Open positions
1
Dealroom signal
75.8/100
Industry
Health, Chemicals
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus
b2b

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Oct 2024 $12M $48M Astia · Impact Science Ventures · Paladin Capital Group · Heritage Medical Systems ↗
SPINOUT✓Other financing Jan 2019 $0 — Caltech, California Institute of Technology —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Aralez Bio website traffic

Latest recorded traffic for Aralez Bio is 1.3K monthly website visits, down 45.8% over the last three months. Aralez Bio's team grew 8.6% over the past year.

Latest monthly visits1.3K 3-month web change-45.8% 1-year team growth+8.6%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

12 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A9 investors entered at this stage

  • Spero Ventures
  • Astia
  • Impact Science Ventures
  • Paladin Capital Group
  • Heritage Medical Systems
  • Freeflow Ventures
  • pineapple group
  • Juniper Networks
  • Good Growth Capital

Other known investors3 additional known investors

  • Caltech, California Institute of Technology
  • Juniper
  • Kotaro Tamura
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
3 countries with
team presence
🇺🇸 United States93.1%
🇸🇬 Singapore3.5%
🇦🇺 Australia3.5%
3 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Aralez Bio on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Aralez Bio’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.